login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Heart failure patients benefit from MitraClip therapy, PERMIT-CARE trial shows


Wednesday, 05 Oct 2011 14:41
Angelo Auricchio
Angelo Auricchio


Results of an observational study presented at the European Society of Cardiology meeting in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular remodeling in patients with mitral regurgitation, who do not respond to cardiac resynchronisation therapy (CRT).


The trial, called PERMIT-CARE, is an investigator-led study evaluating the safety and efficacy of MitraClip treatment in 51 patients with clinically significant functional mitral regurgitation at seven European centres. All patients had unchanged symptoms and unchanged left ventricular volumes after at least six months of CRT. Nearly all patients enrolled in the study were considered ineligible for mitral valve surgery due to a high estimated mortality risk.


Results of the study demonstrate that functional mitral regurgitation reduction with MitraClip treatment is feasible, safe, and leads to substantial improvement in NYHA functional class and reverse left ventricular remodeling in approximately 70% of patients.


“Results of this study suggest that MitraClip treatment could offer, for the first time, a solution for heart failure patients who have severe mitral regurgitation and are unresponsive to CRT,” said Angelo Auricchio, the study’s lead investigator, of the Division of Cardiology at the Fondazione Cardiocentro Ticino in Lugano, Switzerland. “Surgery is not a good option for these patients because of their advanced left ventricular dysfunction and low ejection fraction. We have shown that they were significantly improved following treatment with the MitraClip device. I look forward to additional prospective studies to confirm our findings and to evaluate appropriate timing of MitraClip treatment in heart failure patients.” 


MitraClip
MitraClip

Severe functional mitral regurgitation is common in heart failure patients, including approximately one-third of those indicated for CRT therapy. CRT often reduces mitral regurgitation; however, mitral regurgitation has been reported to persist in about 20–25% of CRT treated patients, and in an additional 10–15% mitral regurgitation may actually worsen after CRT treatment.


Results of the study will be published in an upcoming issue of the Journal of the American College of Cardiology. The MitraClip system is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve, one of the four valves of the heart. The catheter-based MitraClip device is delivered to the heart through the femoral vein, a blood vessel in the leg. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. After treatment, patients are usually home within two to three days and have been observed to recover quickly. The safety and efficacy of the MitraClip system were evaluated in the EVEREST II randomised clinical trial.



Add New Comment

Related Items


Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts
Wednesday, 11 May 2016
A study indicates that women aged less than 55 years with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) have significantly greater comorbidities and worse outcomes than ... Young female acute coronary syndrome patients have significantly greater comorbidities than their male counterparts

Features


Online medical information: A blessing or a curse?
Thursday, 23 Jun 2016
The internet age has enabled patients to access a plethora of medical information. However, a potential drawback is that some of this information is inaccurate or misleading—causing unnecessary ... Online medical information: A blessing or a curse?

“Encouraging” results for transcarotid TAVI
Wednesday, 08 Jun 2016
Darren Mylotte and his co-authors report that TAVI with transcarotid access is “feasible and is associated with encouraging short- and medium-term clinical outcomes”. In this interview, he explains ... “Encouraging” results for transcarotid TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions